Cargando…

An overview of resistance to chemotherapy in osteosarcoma and future perspectives

Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Ortega, Dorian Yarih, Cabrera-Nieto, Sara Aileen, Caro-Sánchez, Haydee Sarai, Cruz-Ramos, Marlid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OAE Publishing Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511812/
https://www.ncbi.nlm.nih.gov/pubmed/36176756
http://dx.doi.org/10.20517/cdr.2022.18
_version_ 1784797720487133184
author Garcia-Ortega, Dorian Yarih
Cabrera-Nieto, Sara Aileen
Caro-Sánchez, Haydee Sarai
Cruz-Ramos, Marlid
author_facet Garcia-Ortega, Dorian Yarih
Cabrera-Nieto, Sara Aileen
Caro-Sánchez, Haydee Sarai
Cruz-Ramos, Marlid
author_sort Garcia-Ortega, Dorian Yarih
collection PubMed
description Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS.
format Online
Article
Text
id pubmed-9511812
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher OAE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-95118122022-09-28 An overview of resistance to chemotherapy in osteosarcoma and future perspectives Garcia-Ortega, Dorian Yarih Cabrera-Nieto, Sara Aileen Caro-Sánchez, Haydee Sarai Cruz-Ramos, Marlid Cancer Drug Resist Review Osteosarcoma (OS) is the most common type of bone sarcoma. Despite the availability of multimodal treatment with surgery and chemotherapy, the clinical results remain unsatisfactory. The main reason for the poor outcomes in patients with OS is the development of resistance to methotrexate, cisplatin, doxorubicin, and ifosfamide. Molecular and cellular mechanisms associated with resistance to chemotherapy include DNA repair and cell-cycle alterations, enhanced drug efflux, increased detoxification, resistance to apoptosis, autophagy, tumor extracellular matrix, and angiogenesis. This versatility of cells to generate chemoresistance has motivated the use of anti-angiogenic therapy based on tyrosine kinase inhibitors. This approach has shown that other therapies, along with standard chemotherapy, can improve responses to therapy in patients with OS. Moreover, microRNAs may act as predictors of drug resistance in OS. This review provides insight into the molecular and cellular mechanisms involved in the development of resistance during the treatment of OS and discusses promising novel therapies (e.g., afatinib and palbociclib) for overcoming resistance to chemotherapy in OS. OAE Publishing Inc. 2022-06-23 /pmc/articles/PMC9511812/ /pubmed/36176756 http://dx.doi.org/10.20517/cdr.2022.18 Text en © The Author(s) 2022. https://creativecommons.org/licenses/by/4.0/© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Review
Garcia-Ortega, Dorian Yarih
Cabrera-Nieto, Sara Aileen
Caro-Sánchez, Haydee Sarai
Cruz-Ramos, Marlid
An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title_full An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title_fullStr An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title_full_unstemmed An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title_short An overview of resistance to chemotherapy in osteosarcoma and future perspectives
title_sort overview of resistance to chemotherapy in osteosarcoma and future perspectives
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9511812/
https://www.ncbi.nlm.nih.gov/pubmed/36176756
http://dx.doi.org/10.20517/cdr.2022.18
work_keys_str_mv AT garciaortegadorianyarih anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT cabreranietosaraaileen anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT carosanchezhaydeesarai anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT cruzramosmarlid anoverviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT garciaortegadorianyarih overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT cabreranietosaraaileen overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT carosanchezhaydeesarai overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives
AT cruzramosmarlid overviewofresistancetochemotherapyinosteosarcomaandfutureperspectives